Legal Representation
Attorney
SCOTT D. WOLDOW
USPTO Deadlines
Next Deadline
7 days remaining
NOA E-Mailed - SOU Required
Due Date
February 08, 2026
Extension Available
Until August 08, 2026
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 8, 2026 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 8, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 8, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jul 8, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jul 8, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 8, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 8, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 8, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 1, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 1, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 1, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 1, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 10, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 8, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 8, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 8, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 8, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 13, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 13, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 24, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 9, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| May 9, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 8, 2023 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| May 8, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| May 8, 2023 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Apr 27, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Feb 8, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Feb 8, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 8, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jan 20, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 20, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 20, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 20, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 20, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 20, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 11, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 28, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 28, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for blood diseases, illnesses and conditions; Pharmaceutical preparations for the treatment or prevention of blood and bleeding disorders; diagnostic preparation for medicinal purposes; Pharmaceutical preparations for immunology, hematology, respiratory, albumin, transplant, inflammatory, and cardiovascular diseases, illnesses, or conditions; Human blood plasma derived pharmaceutical preparations for the treatment of a wide variety of diseases, illnesses or conditions; Pharmaceutical preparations for the treatment of infectious diseases, and diseases caused by bacteria and viruses; vaccines; medicated serums for the treatment of influenza; anti-virals; influenza vaccines; adjuvants and antigens for medical purposes; pharmaceutical preparations, namely, therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; pharmaceutical preparations, namely, reagents for medical and clinical use for typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes
Additional Information
Design Mark
The mark consists of the wording "CSL BEHRING" in stylized form and in the color red, with the letters CSL and B capitalized. The color white represents background and/or transparent area and is not claimed as a feature of the mark.
Color Claim
The color(s) red is/are claimed as a feature of the mark.
Classification
International Classes
005